Chiao-Ling Tsai

Dr. Chiao-Ling Tsai

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Medical Dosimetry
Verified
Journal Article
Closed access
CTChiao-Ling Tsai
Chiao-Ling Tsai
JWJian-Kuen Wu
Jian-Kuen Wu
HCHsiao-Ling Chao
Hsiao-Ling Chao
YTYi-Chun Tsai
Yi-Chun Tsai
JCJason Chia-Hsien Cheng
Jason Chia-Hsien Cheng

16 May 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
WLWei-Lin Liu
Wei-Lin Liu
MGMing Gao
Ming Gao
KTKai-Yuan Tzen
Kai-Yuan Tzen
CTChiao-Ling Tsai
Chiao-Ling Tsai
FHFeng-Ming Hsu
Feng-Ming Hsu
JCJason Chia-Hsien Cheng
Jason Chia-Hsien Cheng
Tumor control of hepatocellular carcinoma by radiotherapy remains unsatisfactory. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a critical role in inhibiting cancer cell death. Elevated PI3K/Akt activity is associated with increased cellular resistance to irradiation. Our aim was to determine whether the inhibition of PI3K/Akt activity by a PI3K inhibitor, BKM120, contributes to the increased sensitivity of liver cancer cells to irradiation. The hepatocellular carcinoma cell lines (Huh7 and BNL) were used to evaluate the in vitro synergism between BKM120 and irradiation. Balb/c mice bearing ectopic BNL xenografts were treated with BKM120 and/or radiotherapy to assess the in vivo response. BKM120 increased cell killing by radiation, increased the expression of apoptotic markers, and suppressed the repair of radiation-induced DNA double-strand breaks. BKM120 pretreatment inhibited radiation-induced Akt phosphorylation and enhanced the tumor-suppressive effect and radiation-induced tumor cell apoptosis in ectopic xenografts. Inhibition of mTOR phosphorylation by rapamycin enhanced the radiosensitivity of BKM120-treated hepatocellular carcinoma cells. The synergism between BKM120 and irradiation likely inhibits the activation of Akt by radiation, leading to increased cell apoptosis and suppression of DNA-double-strand breaks repair in hepatocellular carcinoma cells. These data suggest that the BKM120/radiation combination may be a strategy worthy of clinical trials.

28 January 2016 in Chronobiology International
Verified
Journal Article
Closed access
PDF file
FHFeng-Ming Hsu
Feng-Ming Hsu
WHWei-Hsien Hou
Wei-Hsien Hou
CHChao-Yuan Huang
Chao-Yuan Huang
CWChia-Chun Wang
Chia-Chun Wang
CTChiao-Ling Tsai
Chiao-Ling Tsai
JCJason Chia-Hsien Cheng
Jason Chia-Hsien Cheng
This retrospective study tested the hypothesis that disease control and treatment-related toxicity in patients undergoing high-dose radiotherapy (HDRT) for prostate cancer varies in a circadian manner. Patients with localized prostate adenocarcinoma receiving HDRT (median 78 Gy) to the prostate and involved seminal vesicle(s) without elective pelvic irradiation were divided into a daytime treatment (before 5 PM) group (n = 267) and evening treatment (after 5 PM) group (n = 142). Biochemical failure (Phoenix definition), acute and late gastrointestinal (GI) and genitourinary toxicities (Common Terminology Criteria for Adverse Events version 4), biochemical failure-free survival (BFFS) and freedom from late toxicity were assessed. Analyses were performed by binary logistic regression and Cox proportional hazard regression. The median follow-up was 68 months, and 75% of patients were ≥70 years old. Evening HDRT was significantly associated with worse freedom from ≥grade 2 late GI complications (hazard ratio = 2.96; p < 0.001). The detrimental effect of evening HDRT was significant in patients older than 70 years old (p < 0.001) but not in younger patients (p = 0.63). In a subgroup of propensity score-matched cohort with T2b–T3 disease (n = 154), the 5-year BFFS was worse in the evening group than the daytime group (72% vs. 85%, hazard ratio = 1.95, p = 0.05). Our study indicates that evening HDRT may lead to more GI complications, especially in older patients, and worse BFFS in patients with T2b–T3 disease.

26 December 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
CTChiao-Ling Tsai
Chiao-Ling Tsai
WLWei‐Lin Liu
Wei‐Lin Liu
FHFeng‐Ming Hsu
Feng‐Ming Hsu
PYPo‐Sheng Yang
Po‐Sheng Yang
RYRuoh-Fang Yen
Ruoh-Fang Yen
JCJason Chia-Hsien Cheng
Jason Chia-Hsien Cheng

27 October 2013 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
JCJ.L.-Y. Chen
J.L.-Y. Chen
YHY.-S. Huang
Y.-S. Huang
SKSung-Hsin Kuo
Sung-Hsin Kuo
YCY.-F. Chen
Y.-F. Chen
RHR.-L. Hong
R.-L. Hong
CWChun-Wei Wang
Chun-Wei Wang

13 February 2015 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
CTChiao-Ling Tsai
Chiao-Ling Tsai
FHFeng-Ming Hsu
Feng-Ming Hsu
KTKai‐Yuan Tzen
Kai‐Yuan Tzen
WLWei‐Lin Liu
Wei‐Lin Liu
LCLi-Tzong Chen
Li-Tzong Chen
JCJason Chia-Hsien Cheng
Jason Chia-Hsien Cheng